Hird, A.E. et al. 2020. Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model. Canadian Urological Association Journal. 14, 9 (Mar. 2020), E418–27. DOI:https://doi.org/10.5489/cuaj.6234.